Clinical trial
Subcutaneous Ig NextGen 16% in PID Patients
NCT00391131 · CSL Limited, Industry · Completed
Key facts
| NCT number | NCT00391131 |
|---|---|
| Title | Subcutaneous Ig NextGen 16% in PID Patients |
| Official title | A Multi-centre, Open-label Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Subcutaneous Infusions of Ig NextGen 16% in Patients With Primary Immunodeficiency (PID). |
| Lead sponsor | CSL Limited, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Primary Immunodeficiency (PID) |
| Intervention type | Drug |
| Interventions | IgNextGen 16% |
| Enrollment | 35 |
| Start date | Apr 1, 2007 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Oct 23, 2006 |
| Last update posted | Jun 7, 2012 |
| Countries | Australia, New Zealand |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: